SEI Investments
ACRS icon

SEI Investments’s Aclaris Therapeutics ACRS Stock Holding History

SEI Investments’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$814K Buy
+217,154
New +$733K ﹤0.01% 2452
2025
Q2 		– Sell
-25,189
Closed -$38.5K – 2785
2025
Q1 		$38.5K Buy
+25,189
New +$53.7K ﹤0.01% 2696
2019
Q2 		– Sell
-3,277
Closed -$18K – 2378
2019
Q1 		$18K Sell
3,277
-10,710
-77% -$71K ﹤0.01% 2752
2018
Q4 		$103K Buy
13,987
+13,951
+38,753% +$144K ﹤0.01% 2193
2018
Q3 		$0 Buy
36
+35
+3,500% +$600 ﹤0.01% 2507
2018
Q2 		$0 Sell
1
-1,048
-100% -$19.4K ﹤0.01% 3599
2018
Q1 		$18K Buy
1,049
+169
+19% +$3.58K ﹤0.01% 2676
2017
Q4 		$22K Sell
880
-7,391
-89% -$180K ﹤0.01% 2573
2017
Q3 		$214K Sell
8,271
-2,769
-25% -$74.2K ﹤0.01% 1853
2017
Q2 		$300K Buy
11,040
+10,663
+2,828% +$290K ﹤0.01% 1771
2017
Q1 		$11K Sell
377
-2,223
-86% -$64.1K ﹤0.01% 2441
2016
Q4 		$71K Buy
+2,600
New +$66.3K ﹤0.01% 2043

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SEI Investments's ACRS Position: Q1 2026 in Review

SEI Investments opened a new position in Aclaris Therapeutics (ACRS) in Q1 2026: 217,154 shares worth $814K. The stake represents ﹤0.01% of the portfolio and ranks #2452 among its holdings. This is a return to the name: SEI Investments previously reported a position in ACRS as recently as Q1 2025.

SEI Investments first reported a position in ACRS in Q4 2016 and has held it in 12 quarters since. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • SEI Investments held 217,154 shares of Aclaris Therapeutics worth $814K as of Q1 2026.
  • Aclaris Therapeutics was a new SEI Investments position in Q1 2026.
  • Aclaris Therapeutics made up ﹤0.01% of SEI Investments's portfolio in Q1 2026, its #2452 holding.
  • SEI Investments first reported a position in Aclaris Therapeutics in Q4 2016 and has held it in 12 quarters since.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on SEI Investments's 13F filing for Q1 2026, filed 13 May 2026.